Cresp 25 µG Injection
Darbepoetin alfa
25 µG
Dr. Reddy's Laboratories.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2547.66 NPR |
Available as:
Indications
Cresp 25 µG Injection is used for:
Anaemia of chronic renal failure, Anaemia in chemotherapy patients
Adult Dose
Parenteral
Anaemia of chronic renal failure
Adult: Initially, 0.45 mcg/kg SC/IV once weekly. Alternatively, 0.75 mcg/kg every 2 weeks or 1.5 mcg/kg once monthly via SC inj in patients not on dialysis. Dose may be increased or decreased by 25% once every 4 weeks, according to Hb level. Maintenace dose: 0.45 mcg/kg SC/IV once weekly or once every 2 weeks. Titrate dose to maintain target Hb level.
Subcutaneous
Anaemia in chemotherapy patients
Adult: Initially, 500 mcg once every 3 weeks. Alternatively, 2.25 mcg/kg once weekly. Dose reduction up to 50%, dosing interruption, or discontinuation may be required according to Hb level (refer to detailed product guideline). Discontinue therapy approx 4 weeks after the end of chemotherapy.
Child Dose
Parenteral
Anaemia of chronic renal failure
Child: Initially, 0.45 mcg/kg SC/IV once weekly. Alternatively, 0.75 mcg/kg every 2 weeks or 1.5 mcg/kg once monthly via SC inj in patients not on dialysis. Dose may be increased or decreased by 25% once every 4 weeks, according to Hb level. Maintenace dose: 0.45 mcg/kg SC/IV once weekly or once every 2 weeks. Titrate dose to maintain target Hb level.
Renal Dose
Administration
IV Administration
May be administered SC or IV bolus
Do not shake; vigorous shaking may denature darbepoetin alfa, rendering it biologically inactive
Do not dilute or administer in conjunction with other drug solutions
Discard any unused portion of the vial
Do not pool unused portions
Discontinue immediately if signs/symptoms of anaphylaxis occur
Contra Indications
Hypersensitivity, uncontrolled hypertension.
Precautions
Pregnancy and lactation, children. Hypertension; history of seizures; hepatic impairment; sickle cell anaemia; sudden stabing migraine-like pain (warning sign of hypotensive crisis); exclude other causes of anaemia; ischaemic vascular disease; thrombocytosis; epilepsy; malignant disease; increase in heparin dose may be needed; increased risk of thrombosis when used for anaemia before orthopedic surgery; CV disease including recent MI/cerebrovascular accident. Monitor haemoglobin, BP and electrolytes; platelet count for 1st 8 wk.
Pregnancy-Lactation
Interactions
Antagonism of hypotensive effect and increased risk of hyperkalemia with ACE inhibitors and angiotensin II receptor antagonists. Ethanol.
Adverse Effects
Side effects of Darbepoetin alfa :
>10%
Cancer patients
Fatigue (33%)
Diarrhea (22%)
Edema (21%)
Fever (19%)
Dizziness (14%)
Arthralgia (13%)
Headache (12%)
Death (10%)
Chronic renal failure patients
Infectious disease (24%)
Hyper/Hypotension (20%)
Spasm (17%)
Upper respiratory infection, Headache (15%)
Diarrhea, Vomiting (14%)
Nausea (11%)
Peripheral edema, Dyspnea (10%)
Abdominal pain (10%)
1-10%
Cancer patients
Myalgia (8%)
Hypertension (3.7%)
Pneumonia (3%)
Dyspnea (2%)
Vomiting (2%)
Pulmonary embolism (1.3%)
Chronic renal failure patients
Arthralgia, Cough, Fatigue (9%)
Limb pain (8%)
Dizziness, Fever (7%)
Death (6%)
Edema (6%)
Anemia, DVT, red cell aplasia (5.6%)
Cardiac arrest, Cardiac dysrhythmia, Congestive heart failure (5%)
Myocardial infarction, CVA (2%)
<1%
Cancer patients
Hypertensive encephalopathy (0.6%)
Seizure (0.6%)
Chronic renal failure patients
Hypertensive encephalopathy (<1%)
Seizure (<1%)
Transient ischemic attack (<1% )
Mechanism of Action
Darbepoetin alfa is a biosynthetic form of erythropoietin. It stimulates the division and differentiation of erythroid progenitor cells; reticulocytes are released from the bone marrow and matures into erythrocytes thereby regulating erythropoiesis.
Note
Cresp 25 µG 25 µG Injection manufactured by Dr. Reddy's Laboratories.. Its generic name is Darbepoetin alfa. Cresp 25 µG is availble in Nepal.
Farmaco Nepal drug index information on Cresp 25 µG Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.